Cardiff Oncology, Inc.
CRDFNASDAQHealthcare● Active
$1.50
+$0.00(+0.00%)
Market Cap$102554844
P/E Ratio—
52W High$4.56
52W Low$1.35
Cardiff Oncology, Inc. (CRDF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CRDF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$0.18
Est. -$0.13 · -38.5%
Revenue
$0.00B
Est. $0.00B · -53.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
CRDF reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$0.16 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 14, 2026 | -$0.13 | -$0.18 | -38.5% | $0.00B | $0.00B | -53.7% |
| ▲ Q1 FY2026 | Feb 24, 2026 | -$0.18 | -$0.11 | +38.9% | $0.00B | $0.00B | +134.8% |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$0.20 | -$0.17 | +15.0% | $0.00B | $0.00B | +15.9% |
| ▼ Q3 FY2025 | Jul 29, 2025 | -$0.19 | -$0.21 | -10.5% | $0.00B | $0.00B | +10.6% |
| ▼ Q2 FY2025 | May 8, 2025 | -$0.19 | -$0.20 | -5.3% | $0.00B | $0.00B | +22.1% |
| ▲ Q1 FY2025 | Feb 27, 2025 | -$0.26 | -$0.21 | +19.2% | $0.00B | $0.00B | +60.4% |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.27 | -$0.25 | +7.4% | $0.00B | $0.00B | +135.7% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$0.16
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Miss
EPS Actual
-$0.18
EPS Est.
-$0.13
EPS Surpr.
-38.5%
Revenue
$0.00B
Q1 FY2026
Feb 24, 2026Beat
EPS Actual
-$0.11
EPS Est.
-$0.18
EPS Surpr.
+38.9%
Revenue
$0.00B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.17
EPS Est.
-$0.20
EPS Surpr.
+15.0%
Revenue
$0.00B
Q3 FY2025
Jul 29, 2025Miss
EPS Actual
-$0.21
EPS Est.
-$0.19
EPS Surpr.
-10.5%
Revenue
$0.00B
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$0.20
EPS Est.
-$0.19
EPS Surpr.
-5.3%
Revenue
$0.00B
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
-$0.21
EPS Est.
-$0.26
EPS Surpr.
+19.2%
Revenue
$0.00B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.25
EPS Est.
-$0.27
EPS Surpr.
+7.4%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.69 | $-0.37 | $-0.10 | 3 |
| Q3 FY2028 | $-0.67 | $-0.36 | $-0.10 | 3 |
| Q2 FY2028 | $-0.62 | $-0.33 | $-0.09 | 3 |
| Q1 FY2028 | $-0.55 | $-0.30 | $-0.08 | 3 |
| Q4 FY2027 | $-0.47 | $-0.25 | $-0.07 | 2 |
| Q3 FY2027 | $-0.45 | $-0.24 | $-0.07 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 14, 2026 | -38.5% | $1.69 | $1.73 | +2.37% |
| ▲ Q1 FY2026 | Feb 24, 2026 | +38.9% | $1.56 | $1.70 | +8.97% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +15.0% | $2.24 | $2.25 | +0.45% |
| ▼ Q3 FY2025 | Jul 29, 2025 | -10.5% | $3.73 | $3.31 | -11.26% |
| ▼ Q2 FY2025 | May 8, 2025 | -5.3% | $2.49 | $2.63 | +5.62% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +19.2% | $4.46 | $4.06 | -8.97% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +7.4% | $3.81 | $4.09 | +7.35% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -4.0% | $2.14 | $2.13 | -0.47% |
Q2 FY2026+2.37%
Report Date
May 14, 2026
EPS Beat/Miss
-38.5%
Price Before
$1.69
Price After
$1.73
Q1 FY2026+8.97%
Report Date
Feb 24, 2026
EPS Beat/Miss
+38.9%
Price Before
$1.56
Price After
$1.70
Q4 FY2025+0.45%
Report Date
Nov 6, 2025
EPS Beat/Miss
+15.0%
Price Before
$2.24
Price After
$2.25
Q3 FY2025-11.26%
Report Date
Jul 29, 2025
EPS Beat/Miss
-10.5%
Price Before
$3.73
Price After
$3.31
Q2 FY2025+5.62%
Report Date
May 8, 2025
EPS Beat/Miss
-5.3%
Price Before
$2.49
Price After
$2.63
Q1 FY2025-8.97%
Report Date
Feb 27, 2025
EPS Beat/Miss
+19.2%
Price Before
$4.46
Price After
$4.06
Q4 FY2024+7.35%
Report Date
Nov 7, 2024
EPS Beat/Miss
+7.4%
Price Before
$3.81
Price After
$4.09
Q3 FY2024-0.47%
Report Date
Aug 8, 2024
EPS Beat/Miss
-4.0%
Price Before
$2.14
Price After
$2.13
Avg Beat Reaction+1.95%
Avg Miss Reaction-0.94%
Beat Rate4 / 8 quarters
Largest Move-11.26% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CRDF ends December
Cardiff Oncology, Inc. (CRDF) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-0.18 — missing the analyst consensus of $-0.13 by -38.5%. The next CRDF earnings date is expected around September 1, 2026.
Each quarter, investors track CRDF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CRDF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CRDF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CRDF earnings · 5 questionsCardiff Oncology, Inc.'s next earnings report is expected around September 1, 2026. CRDF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CRDF historically reports after market close (AMC).
CRDF earnings datewhen is CRDF earningsCRDF next earnings datewhen does CRDF report earningsCRDF earnings calendar
▸ Source: FMP · Cardiff Oncology, Inc. SEC filings · US GAAP · Cardiff Oncology, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026